Pathogenesis of Cholangiocarcinoma.

chemoresistance cholangiocarcinoma epigenetics genomics molecular pathogenesis targeted therapies

Journal

Annual review of pathology
ISSN: 1553-4014
Titre abrégé: Annu Rev Pathol
Pays: United States
ID NLM: 101275111

Informations de publication

Date de publication:
24 01 2021
Historique:
pubmed: 3 12 2020
medline: 1 4 2021
entrez: 2 12 2020
Statut: ppublish

Résumé

Cholangiocarcinoma (CCA) encompasses a group of malignancies that can arise at any point in the biliary tree. Although considered a rare cancer, the incidence of CCA is increasing globally. The silent and asymptomatic nature of these tumors, particularly in their early stages, in combination with their high aggressiveness, intra- and intertumor heterogeneity, and chemoresistance, significantly compromises the efficacy of current therapeutic options, contributing to a dismal prognosis. During the last few years, increasing efforts have been made to unveil the etiologies and pathogenesis of these tumors and to develop more effective therapies. In this review, we summarize current findings in the field of CCA, mainly focusing on the mechanisms of pathogenesis, cells of origin, genomic and epigenetic abnormalities, molecular alterations, chemoresistance, and therapies.

Identifiants

pubmed: 33264573
doi: 10.1146/annurev-pathol-030220-020455
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

433-463

Auteurs

Pedro M Rodrigues (PM)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.
National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Paula Olaizola (P)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.

Nuno A Paiva (NA)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.

Irene Olaizola (I)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.

Alona Agirre-Lizaso (A)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.

Ana Landa (A)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.

Luis Bujanda (L)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.
National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Maria J Perugorria (MJ)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.
National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Instituto de Salud Carlos III, 28029 Madrid, Spain.

Jesus M Banales (JM)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), 20014 San Sebastian, Spain; email: jesus.banales@biodonostia.org, pedro.rodrigues@biodonostia.org.
National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH